



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 65155

**Title:** Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

**Reviewer's code:** 04091850

**Position:** Editorial Board

**Academic degree:** DSc, MD, PhD

**Professional title:** Adjunct Professor, Chief Doctor

**Reviewer's Country/Territory:** Denmark

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-08 06:10

**Reviewer performed review:** 2021-04-11 07:36

**Review time:** 3 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

The topic of the manuscript is of major importance for colleagues working within the fields of IBD and hepatology. In general the paper is well disposed and well written although some minor corrections have to be made regarding the language throughout mostly in the sections dealing with drug induced liver disease in IBD. Besides it is a problem reviewing the manuscript that the pages does not seem to be numbered

Specific comments for consideration: Key words: Viral hepatitis should be added

Primary sclerosing cholangitis: Regarding aetiology of the disease it is stated that environmental factors may play a role. Could this be specified somewhat? Overlap syndromes between PSC and AIH are mentioned which is highly relevant. I miss a short section regarding the relation between AIH in its own and IBD. Although the occurrence of both IBD and AIH is rather rare AIH is more prevalent in IBD than in the general population (e.g. Halling et al., World J Gastroenterology 2017) Omit "other" from the head line "other non-immune-mediated disorders

Portal vein thrombosis: The incidence of thromboembolic complications is 2.6/1000 persons/year. Is this the incidence of all cases of thrombosis or does the given incidence relate only to portal vein thrombosis?

Thiopurines: The importance of the 6-MMP metabolite for the occurrence of hepatotoxicity is noted. However it would have been highly relevant to briefly describe the concept of shunting and the possibility to treat shunters by reducing the dose of azathioprine and the addition of allopurinol.

Methotrexate: Two different incidence rates regarding transaminase elevation in patients treated with methotrexate are given 1.4 per 100 patient months and 0.9 per 100 patient months. As I see it these numbers are taken from the same reference. An explanation for this different incidence rates are needed

Anti-interleukin 12/23: The risk of HBV reactivation is noted. This risk is not specific for anti-interleukin 12/23 treatment and the subject is touched upon



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

in the sections regarding IBD and viral hepatitis B and C. Figure 1: In the box "First line tests" fibroscan could be added.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 65155

**Title:** Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

**Reviewer's code:** 05343234

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-12 06:37

**Reviewer performed review:** 2021-04-21 10:17

**Review time:** 9 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

The review article entitled "Hepatobiliary disorder associated with inflammatory bowel disease" summarized hepatobiliary complications associated with IBD. The article is precise and well-written, and covering considerable situation to date. This review is helpful for readers. Please correct follows. 1. There are several abbreviations which do not spell out. "RUC" in page 4, "MRCP, magnetic resonance cholangiopancteatography" in page 6, "AP" in page 13. 2. If REL, IL2, CARD9 are gene names, please be italicized in page 5.